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Abstract
Nasopharyngeal carcinoma (NPC) is a highly invasive epithelial malignancy that is prevalent in southern China and
Southeast Asia. It is consistently associated with latent Epstein–Barr virus (EBV) infection. In NPC, miR-BARTs,
the EBV-encoded miRNAs derived from BamH1-A rightward transcripts, are abundantly expressed and contribute
to cancer development by targeting various cellular and viral genes. In this study, we establish a comprehensive
transcriptional profile of EBV-encoded miRNAs in a panel of NPC patient-derived xenografts and an EBV-positive
NPC cell line by small RNA sequencing. Among the 40 miR-BARTs, predominant expression of 22 miRNAs was
consistently detected in these tumors. Among the abundantly expressed EBV-miRNAs, BART5-5p, BART7-3p,
BART9-3p, and BART14-3p could negatively regulate the expression of a key DNA double-strand break (DSB) repair
gene, ataxia telangiectasia mutated (ATM), by binding to multiple sites on its 3’-UTR. Notably, the expression of
these four miR-BARTs represented more than 10% of all EBV-encoded miRNAs in tumor cells, while downregulation
of ATM expression was commonly detected in all of our tested sequenced samples. In addition, downregulation of
ATMwas also observed in primary NPC tissues in both qRT-PCR (16 NP and 45 NPC cases) and immunohistochemical
staining (35 NP and 46 NPC cases) analysis. Modulation of ATM expression by BART5-5p, BART7-3p, BART9-3p,
and BART14-3p was demonstrated in the transient transfection assays. These findings suggest that EBV uses
miRNA machinery as a key mechanism to control the ATM signaling pathway in NPC cells. By suppressing these
endogenous miR-BARTs in EBV-positive NPC cells, we further demonstrated the novel function of miR-BARTs in
inhibiting Zta-induced lytic reactivation. These findings imply that the four viral miRNAs work co-operatively to
modulate ATM activity in response to DNA damage and to maintain viral latency, contributing to the tumorigenesis
of NPC.
© 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Nasopharyngeal carcinoma (NPC) is an invasive epithe-
lial malignancy arising from the most superior part
of the nasopharynx. Due to the obscure location and
radio-sensitivity of cancer cells, the combination of
chemotherapy and radiotherapy is currently used as the
mainstay treatment of advanced disease [1]. However,
the outcomes in patients with distantmetastases or recur-
rence are still poor and survivors also frequently suffer
© 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
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from severe side effects. Hence, the development of
effective treatment strategies for NPC patients is still the
main focus of the field.
In NPC, clonal EBV genomes have consistently been
detected in both high-grade dysplasia lesions and inva-
sive tumors, implying the crucial role of EBV infection
in NPC tumorigenesis. EBV resides in NPC cells as
a type II latent infection, in which only viral EBNA1
and LMPs proteins are expressed [2,3]. The oncogenic
properties of these viral proteins in epithelial malignan-
cies have been well characterized [4,5]; LMPs always
activate the host immune response [6]. Therefore,
in NPC, these viral proteins are usually variable and
expressed at low levels to escape from the host’s cellular
defense system, thereby maintaining viral latency. In
contrast, the non-immunogenic virus-encoded miR-
NAs in the long viral BamH1-A rightward transcripts
(BARTs) region, miR-BARTs, are abundantly expressed
in EBV-infected epithelial malignancies, such as
NPC and lymphoepithelioma-like carcinomas [7]. The
functional roles of miR-BARTs have been reported
to control viral latency [8–10], host cell immunity
[11–13], cell proliferation [14], apoptosis [15–17],
and metastasis [18]. Increasing evidence has been
reported to support the notion that these EBV-encoded
miRNAs are the key molecules in augmenting NPC
tumorigenesis.
Various studies have clearly demonstrated the vital
roles of miRNAs in modulating cell radio-sensitivity
by targeting specific DNA repair factors [19]. For
example, ectopic expression of miR-101, miR-181a,
and miR-421 in different cancer cell lines can suppress
endogenous ataxia telangiectasia mutated (ATM) gene
expression and sensitize cells to ionizing radiation
(IR) treatment [19–22]. Intriguingly, it had previously
been reported that ATM is consistently downregulated
in EBV-positive primary NPC samples [23]. In vitro
EBV re-infection in nasopharyngeal epithelial cells
has been able to suppress endogenous ATM expression
and, sequentially, ATM kinase activity followed by
exposure to IR [23]. The indispensable role of ATM in
viral replication was also demonstrated in our recent
study [24]. However, the involvement of EBV in ATM
regulation has remained elusive and needs further
investigation.
In this study, we examined EBV-miRNA expression
profiles in a panel of NPC patient-derived xenografts and
an EBV-positive NPC cell line by high-throughput small
RNA sequencing (RNA-seq). Although miR-BARTs are
processed from the same primary transcript, several of
them were predominantly expressed. Most importantly,
we discovered that some highly expressed miR-BARTs
could directly regulate ATM expression. Manipulating
the expression of those specific miR-BARTs in the cells
alters both IR sensitivity and Zta-induced EBV reacti-
vation via the ATM signaling pathway. This is the first
study to uncover the role of miR-BARTs in modulating
the expression of ATM, a critical DNA double-strand
break responder.
Materials and methods
Cell lines, xenografts, and patient samples
Five EBV-positive NPC xenografts (xeno-666,
xeno-2117, xeno-1915, C15, and C17), a native
EBV-infected NPC-derived cell line (C666-1), three
immortalized nasopharyngeal epithelial cell lines
(NP361, NP550, and NP69), and HeLa cells were
used in the study [11,25,26]. In addition, a cohort
of frozen specimens, including 16 non-cancerous
nasopharyngeal epithelia (NP) and 45 primary NPC
samples, were used in RT-qPCR analysis (supple-
mentary material, Table S1). Another 35 NP and 46
NPC paraffin-embedded specimens were recruited
for IHC analysis (supplementary material, Table S2).
The primary specimens were prospectively collected
at the Prince of Wales Hospital, Hong Kong. Ethical
approval was obtained from the Joint CUHK/NTEC
Clinical Research Ethics Committee, Hong
Kong.
Small RNA sequencing (RNA-seq)
Total RNAs were extracted from fresh samples using
TRIzol reagent (Life Technologies, Carlsbad, CA,
USA). The small RNA libraries were prepared using the
Illumina TruSeq Small RNA Library Prep Kit according
to the manufacturer’s instructions. Single-end 51-bp
sequencing was performed on an Illumina HiSeq2000
sequencing system. Sequenced reads were aligned to
human (hg19) and EBV genomes (accession number
AJ507799) using Bowtie 2 [27]. The expression level
of each annotated miRNA was computed based on
sequencing reads that support the miRNA sequence
defined in the miRBase database (http://www.mirbase
.org/). Specifically, a read was considered to support
a miRNA if its alignment with the miRNA sequence
had at least 16 matched nucleotides. The read depth
of the mature sequences was aligned using SAMtools
and normalized per 10 million miRNAs sequenced
[28]. The heterogeneity of the sequencing reads was
examined and the results for the miR-BARTs of interest
in C666-1 are listed in the supplementary material,
Table S3.
Target prediction
The miRanda and RNAhybrid programs were used for
miR-BART target prediction as described previously
[11,17].
Reverse transcription-quantitative PCR (RT-qPCR)
Total RNA was first reverse-transcribed using the
miScript Reverse Transcription Kit (Qiagen, Hilden,
Germany). The ATM RT-PCR product was amplified
using the SYBR Green PCR Master Mix Kit (Applied
Biosystems, Foster City, CA, USA). The data were nor-
malized with β-actin and the fold-change was calculated
using the 2(−ΔΔCt) method. The primer sequences for the
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PCR are listed in the supplementary material, Table S4.
The quantitative method and the oligonucleotide
sequences used for EBV-miRNA expression have been
described previously [7,12].
miRNA mimics, inhibitors, expression vectors,
and transfection
All of the miRNA mimics, inhibitors, and their
negative controls were synthesized by Ambion
Inc (Austin, TX, USA) and the information is
listed in the supplementary material, Table S5. The
ATM-specific siRNAs were from GenePharma (Shang-
hai, China) and the sequences were as follows: sense,
5’-CAUACUACUCAAAGACAUUdTdT-3’; anti-
sense, 5’-AAUGUCUUUGAGUAGUAUGTT-3’
[24]. The ATM expression vector pcDNA3.1 (+)
Flag-His-ATM WT was a gift from Michael Kas-
tan (Addgene #31985) [29]. The pcDNA3.1 (+)
HA-BZLF1, C666-1-BART-Cluster 1 miRNA, and
C666-1-BART-Cluster 2 miRNA expression vec-
tors have been described previously [12,24]. In the
experiment, 50 nM of siRNA, 20 nM of miRNA
mimic/inhibitor, and 2.5 μg of expression vector were
used to transfect the cells in a six-well plate format. All
of the transfections were performed with Lipofectamine
2000 (Invitrogen, Carlsbad, CA, USA) unless otherwise
specified.
Immunohistochemistry (IHC)
IHC staining was performed using the Polymer Refined
Detection Kit on a Bond-Max fully automated staining
system [30]. ATM-IHC was carried out with a primary
antibody against ATM (1:1000 dilution, clone 11G12;
Abcam, Cambridge, MA, USA) and all of the slides
were counterstained with hematoxylin for analysis.
The results were evaluated by a semi-quantitative
approach to assign an H-score to each sample. The
nuclear staining intensity (0, 1+, 2+ or 3+) and the
percentage of cells at each staining intensity level were
determined. The H-score was calculated using the
following formula: [1 × (% cells 1+) + 2 × (% cells
2+) + 3 × (% cells 3+)]. Samples with H-scores higher
than 100 were considered ATM expression-positive.
Statistical analysis was performed using SPSS 19.0
(IBM Corp, Armonk, NY, USA) and chi-square tests
were used to analyze the significance of differences
in protein expression scores in normal and tumor
tissues.
Antibodies and immunoblotting
The antibody against BHRF1 was a gift from Jaap
Middeldorp (VU University Medical Centre, The
Netherlands). Antibodies against BZLF1 and BRLF1
were purchased from Argene (bioMérieux SA, Marcy
l’Etoile, France). The rabbit monoclonal antibodies
against phospho-ATM (ab81292), ATM (ab32420),
and the anti-HA tag (1:5000 dilution; ab9110) rabbit
polyclonal antibody were purchased from Abcam.
The anti-γ-H2AXser139 antibody was purchased from
EMD Millipore (Quincy, MA, USA). The antibodies
against CHK2 (#3440) and phospho-CHK2 (#2197)
were purchased from Cell Signaling Technology (Dan-
vers, MA, USA). All of the AlexaFluor-conjugated
and HRP-conjugated secondary antibodies were pur-
chased from Molecular Probes (New York, NY, USA).
The HRP-conjugated secondary antibodies were pur-
chased from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). Western blot analysis was performed as
previously described [24] and all the primary and the
secondary antibodies used is 1:1000 and 1:5000 in dilu-
tions unless otherwise specified. The signal intensity
was measured by ImageJ software (http://rsb.info.nih
.gov/ij/).
Luciferase reporter assay
The construction of reporter plasmids and the proce-
dure of the dual luciferase reporter assay have been
described previously [31,32]. The sequences of the
oligonucleotides for plasmid construction are listed in
the supplementarymaterial, Table S6. In the experiment,
transfection complex containing 80 ng of reporter plas-
mid, 8 ng of pRL-CMV-control plasmid, and 1 nM of
miRNA mimic/inhibitor was co-transfected into 293FT
cells in 24-well plates.
Ionizing radiation (IR), γ-H2AX staining, comet
assay, and clonogenic survival assay
The indicated dose of IR was delivered with a
cesium-137 source from an MDS Nordion Gamma-
cell 1000 Elite Irradiator. The γ-H2AX staining analysis
was performed as previously described [33]. The comet
assays were performed using an OxiSelect Comet
Assay Kit from Cell Biolabs, Inc (San Diego, CA,
USA) according to the manufacturer’s instructions. At
least 70 cells were analyzed using ImageJ software
and the DNA repair capacity was measured by com-
paring the tail moment between miR-BART transfected
cells at 30 min and 6 h post-IR treatment. The stan-
dard clonogenic survival assays have been described
previously [34].
Statistical analysis
The data were analyzed using Student’s t-test unless
otherwise specified. The analysis of each sample was
performed in triplicate. The results are expressed as
the mean ± SD. To assess the similarity of miR-BART
expression patterns of the NPC samples, Spearman’s
rank and Pearson’s correlations were computed for the
miR-BART reads/10 million miRNAs sequenced across
the samples. The expression pattern of an miRNA is
described as considerably different if Cook’s distance
statistic D between any pair of sample exceeds 4/n,
where n is the number of miR-BARTs considered [35].
All of the analyses were performed using GraphPad
Prism 5 (GraphPad Software, Inc, San Diego, CA,
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Table 1. Percentage of EBV-miRNAs found in small-RNA sequencing of EBV-associated NPCs
No of reads No of miRNAs
Library Total Mapped to human Mapped to EBV Human EBV % of EBV-miRNAs
C666-1 17 925 005 13 451 374 4 049 298 9 709 760 4 029 708 29.33
X666 17 987 157 12 305 340 4 860 335 8 819 204 4 826 139 35.37
X2117 19 820 159 15 573 415 2 533 990 7 037 414 2 500 278 26.22
X1915 15 761 052 11 177 098 1 448 822 2 702 222 1 417 860 34.39
C15 15 087 966 10 506 729 1 686 724 2 591 004 1 630 218 38.62
C17 20 032 126 16 429 769 45 411 1 736 005 37 189 2.10
Figure 1. Expression of viral miRNAs in EBV-positive NPCs. (A) The number of EBV-miRNA reads is indicated per 10 million of the total
mapped mature miRNAs to normalize the sequencing depth in each library. The libraries of C666-1, C17, and the average of four primary
NPC-derived xenografts (xeno-C666, xeno-2117, xeno-1915, and C15) are shown as mean ± SD. (B) The distribution of the individual
miR-BARTs to the total viral miRNAs in the libraries is shown in the pie charts.
© 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2018; 244: 394–407
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Figure 2. Legend on next page.
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USA). A value of p < 0.05 was taken to indicate sta-
tistical significance.
Results
Expression profiles of viral miRNAs in EBV-positive
NPC
To explore the EBV-encoded miRNA expression pat-
terns in NPC, we performed small RNA-seq on six
NPC samples, including the C666-1 cell line, four NPC
xenografts derived from primary tumors (xeno-666,
xeno-2117, xeno-1915, and C15), and one xenograft
(C17) derived from cutaneous metastasis [36–38]. In
each sample, 15–20 million reads mapped to either
human or EBV genomes were obtained for analy-
sis. Curiously, almost all of the reads mapped to the
EBV genome were known EBV-encoded miRNAs,
indicating that miRNAs are the major components of
EBV-derived small RNAs in NPC despite the exis-
tence of other small viral-encoded RNAs, such as
v-snoRNA-1 and ebv-sisRNA-1, being reported recently
[39]. As shown in Table 1, we obtained 25–40% of the
EBV-encoded miRNAs from the total miRNA reads in
each sample. However, a relatively smaller abundance
of EBV-encoded miRNAs (2.1%) was found in C17.
The low expression of miR-BARTs in C17 may be due
to the selection of a metastatic subclone in a distinct
microenvironment. Although microRNAs derived from
the viral BHRF1 transcript (miR-BHRF1) have been
suggested to restrict expression in type III latent infec-
tions, a few copy numbers ofmiR-BHRF1were detected
in the samples (supplementary material, Table S7). The
observation aligns with our previous finding of low
BHRF1 lytic transcript expression levels in NPCs [7].
The miR-BART expression pattern in C666-1 in
our data was similar to the recent massive amount of
sequencing data from two independent teams (supple-
mentary material, Figure S1) [40,41]. Remarkably, this
expression pattern was also significantly similar across
the six tested NPC samples (Spearman’s rank close
to 0.9, p < 0.01) (supplementary material, Figure S2),
although the expression levels of some highly expressed
miRNAs were considerably different across several
tumor lines (Cook’s distance ≥ 4/n) (Figure 1A and
supplementary material, Table S8). These highly
expressed miRNAs included BART5-5p, BART6-3p,
BART7-3p, BART8-5p, BART10-3p, BART19-3p, and
BART22, occupying up to 60% of the total viral miR-
NAs in NPCs (Figure 1B). We found particularly low
expression of BART20 and BART21 in all NPC samples.
Similar observations have also been reported in other
EBV-positive epithelial malignancies [7]. The expres-
sion of individual EBV-miRNAs in each tumor line is
summarized in the supplementary material, Table S7.
ATM is a direct target of EBV-encoded miRNAs
We have previously demonstrated that the ATM protein
is consistently downregulated in EBV-positive NPC
and contributes to viral replication during EBV lytic
reactivation in epithelial cells [23,24]. Based on these
findings, we hypothesize that the highly expressed
miR-BARTs are responsible for ATM regulation and
subsequently inhibiting EBV lytic reactivation in NPC
cells. We attempted to predict the putative miR-BART
binding sites, specifically on the ATM transcript by
using miRanda and RNAhybrid algorithms. The abun-
dantly expressed miRNAs identified in small RNA-seq
were prioritized for the analysis. Using the default set-
tings for in silico prediction, multiple putative binding
sites of miR-BARTs (BART5-5p, BART7-3p, BART9-3p,
and BART14-3p) on the ATM 3’-untranslated region
(3’-UTR) were suggested (Figure 2A). These four
miRNAs covered up to 10% and 11% of the total viral
miRNAs in C666-1 and NPC xenografts, respectively
(Figure 1B). Notably, the high expression levels of
BART5-5p, BART7-3p, BART9-3p, and BART14-3p
in primary NPC tissues were also corroborated by
RT-qPCR (Figure 2B). Of note, western blot analysis
revealed downregulation of ATM expression in the
EBV-positive NPC samples (Figure 2C and supple-
mentary material, Figure S3A). The reduction of ATM
expression in NPC was further substantiated in the IHC
analysis in an independent cohort of 35 histologically
Figure 2. ATM is a potential target of several EBV-encoded miRNAs. (A) Suggested putativemiR-BART recognition sites on the ATM 3’-UTRs
are shown. The seed-binding regions of themiR-BARTs are underlined and the bases mutated for the luciferase reporter analysis are marked
in red. (B) The expression of miR-BARTs of interest in primary NPC samples was examined using RT-qPCR (n = 45). The expression of
miR-BARTs was normalized to EBNA1 for analysis. The low-expression miR-BARTs (BART21-5p and BART20-3p) and other high-expression
miR-BARTs were included for comparison. The data shown are the mean± SEM from the tested samples. (C) Immunoblotting of ATM protein
in the NPC samples. Three immortalized normal NP cell lines (NP361, NP550, and NP69), C666-1, and five NPC xenografts (xeno-C666,
xeno-2117, xeno-1915, C15, and C17) were analyzed. (D) ATM protein expression in FFPE specimens was analyzed by immunohistochemistry.
NP-1 and NP-2 are examples of normal NP epithelia with strong ATM positive stain. NPC-1 and NPC-2 are examples of NPC cells that are
negative for ATM expression. The infiltrated lymphocytes that served as internal controls were strongly positive. NPC-3 is an example of
NPC cells that are positive for ATM (original magnification × 400). (E) Expression of ATM in the primary NPC samples was demonstrated
by RT-qPCR (number of NPs = 16; number of NPCs = 45). (F) The scatter plot demonstrates the inverse correlation between the miR-BART
of interest and ATM mRNA expression levels in 25 NPC samples. (G) The direct interaction between ATM expression and miR-BARTs was
demonstrated in dual luciferase reporter assays. The pMIR-REPORT vectors containing the wild-type ATM binding sites (UTR-wt) or the
mutant binding sites (UTR-mut) were tested against the corresponding miR-BART mimics and inhibitors. The relative firefly luciferase
activity was normalized to the Renilla luciferase control, and results were taken from at least three independent experiments. The data
shown are the mean + SD. miR-Ctl = miR-BART mimic control; miR-BART = miR-BART mimic; Inh-NEG = miRNA inhibitor negative
control; Inh-BART = miR-BART inhibitor. **p < 0.01; ***p < 0.001.
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Figure 3. Modulation of ATM expression by EBV-encoded miRNAs. (A) Downregulation of ATM in NP69 and HeLa cells by ebv-miRNAs from
both clusters. Cells transfected with expression vectors containing BART -Cluster 1 (miR-BART-C1) and BART -Cluster 2 (miR-BART-C2)
derived miRNAs or individual miR-BARTs were analyzed by western blotting. The empty vector and irrelevant miRNA mimic were used as
negative controls. (B, C) The ATM expression of BART -Cluster 1 (C1) and BART -Cluster 2 (C2) miRNA expressing cells was restored by the
indicated miR-BART inhibitors (Inh-BARTs). Endogenous ATM expression was measured by western blot and the relative ATM expression
is shown under the blots. (D) Endogenous ATM protein expression in C666-1 cells was restored by the miR-BART inhibitors. The inhibitors
of BART5-5p, BART7-3p, BART9-3p, and BART14-3p were introduced, individually or together (All 4 Inh-BARTs), into the C666-1 cells and
protein lysates were collected 48 h post-transfection for western blot analysis.
normal nasopharyngeal epithelia (NP) and 46 primary
NPC tumor cases (p < 0.0001) (Figure 2D). Positive
ATM expression was generally observed in the normal
NP cases (n = 32, 91.4%), whereas 31 NPC cases
(67.4%) scored negative (supplementary material,
Table S9). Positive ATM expression was also iden-
tified in one primary EBV-negative NPC specimen,
which was expected to have no miR-BART expression
(supplementary material, Figure S3B). In addition, the
expression level of the ATM transcript in primary NPC
tumors (n = 45) also showed a significant reduction
compared with those in the non-cancerous NP tissues
(n = 16; p = 0.0003) in RT-qPCR analysis (Figure 2E).
The relationship between ATM and miR-BART
expression was further investigated by directly compar-
ing their mRNA expression levels in the primary NPCs.
We observed a strong inverse association between
ATM mRNA and BART5-5p, BART7-3p, BART9-3p,
and BART14-3p expression (−0.5306 < Spearman r
< −0.4481; 0.0016 < p < 0.0475) (Figure 2F). To
validate the direct interaction of the miR-BARTs with
ATM-3’-UTR, we performed a series of luciferase
reporter assays with co-transfection of different com-
binations of miR-BART mimics and reporter plasmids
into 293FT cells. The luciferase activity of the reporter
plasmids containing a predicted ATM-3’-UTR recog-
nition site was strongly repressed by BART5-5p,
BART7-3p, BART9-3p, and BART14-3p (p < 0.01 in
all combinations). However, the suppressive effect was
canceled if the corresponding miR-BART inhibitor was
co-transfected simultaneously. The inhibitory effect
was also not suggested when the complementarities
of the seed region on the binding site were either
mutated or deleted (Figure 2G and supplementary
material, Figure S4). Together, these results support
the notion that multiple miR-BARTs directly modulate
ATM expression via their specific binding sites on the
3’-UTR.
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Figure 4. EBV-miRNAs enhance the ionizing radiation (IR) sensitivity of epithelial cells. The miR-BART transfected cells were treated with
different doses of IR and the cells were harvested at 30 min post-irradiation for immunoblotting analysis. The expression of the basal
ATM proteins, phospho-ATM (p-ATM), phospho-CHK2 (p-CHK2), and γ-H2AX, was analyzed. Actin was probed as the loading control. ATM
knockdown cells (siATM) were included as positive controls.
Regulation of endogenous ATM expression
by EBV-encoded miRNAs
To illustrate the strong regulatory effect of
EBV-encoded miRNAs on ATM, we introduced
an expression vector of C666-1-BART-Cluster 1,
C666-1-BART-Cluster 2 or a mimic of BART5-5p,
BART7-3p, BART9-3p, and BART14-3p into two
EBV-negative ATM-expressing epithelial cells,
NP69 and HeLa. The presence of either individual
miR-BART-Cluster vector or miRNA mimic notably
repressed ATM expression (Figure 3A). Interestingly,
synergistic suppressive effects were observed on ATM
expression in HeLa cells were observed when the
cells were simultaneously transfected with either both
miR-BART-Cluster vectors or the mimics of all four
miR-BARTs (Figure 3A and supplementary material,
Figure S5A).
To further strengthen evidence for the importance of
miR-BART in ATM expression, additional experiments
with miRNA inhibitors were performed. The specificity
of the miR-BART inhibitors has been confirmed by
RT-qPCR. In individual miR-BART inhibitor trans-
fected C666-1, the expression of the targetedmiR-BART
was dramatically repressed, whereas no obvious effect
was detected in the previously reported ATM regulated
miRNAs, primary BARTs, and other miR-BARTs, which
are located in close proximity to the miR-BARTs of
interest (supplementary material, Figures S6 and S7).
In BART-Cluster 1 and BART-Cluster 2 expressing
NP69 and HeLa cells, ATM expression was restored by
co-transfecting with BART5-5p, BART7-3p, BART9-3p
or BART14-3p inhibitors (Figure 3B, C). Likewise,
ATM expression was also restored by inhibiting endoge-
nous BART7-3p, BART9-3p, and BART14-3p activity,
individually or together, in C666-1 cells (Figure 3D).
The reason for the inability of the BART5-5p inhibitor
to restore ATM expression in C666-1 is unclear.
Endogenous BART5-5p is functionally active in C666-1
because we previously demonstrated its regulatory
effect on PUMA in the same cells [17]. In addition,
low expression of hsa-miR-18a/b, which shares signif-
icant seed homology with BART5-5p, and no sequence
© 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2018; 244: 394–407
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Figure 5. Legend on next page.
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variation on the putative binding site were identified
in C666-1 (unpublished data), indicating that the puta-
tive BART5-binding site is probably available on the
ATM-3’-UTR in C666-1. However, the involvement of
the cell-specific mechanisms to shield the BART5-5p
recognition site on the ATM-3′ UTR cannot be ruled
out. Overall, the findings imply roles for BART5-5p,
BART7-3p, BART9-3p, and BART14-3p in regulating
ATM expression.
EBV-miRNAs enhance the ionizing radio-sensitivity
of epithelial cells
We postulated that the expression of miR-BARTs may
enhance the radio-sensitivity of NPC cells through ATM
suppression. Thus, we examined the contribution of
miR-BARTs to the DNA damage response. NP69 and
HeLa cells were transfected with either ATM-specific
siRNA or miR-BART mimics and exposed to differ-
ent doses of γ-irradiation afterwards. The IR-induced
ATM activity, as indicated by the phosphorylation of
both ATM and its downstream targets (γ-H2AX and
p-CHK2), was clearly observed in the control trans-
fected cells in a dose-dependent manner, without any
apparent differences in the total ATM protein levels
(Figure 4). However, the magnitude of the induced ATM
activity was dramatically reduced in cells where ATM
expression was knocked down by the siRNA. Similarly,
the magnitude of the IR-induced responses in the cells
expressing miR-BARTs, individually or together, were
also obviously reduced (Figure 4). We subsequently
extended our study to examine the post-IR recovery
ability of the cells. In the cells exposed to 3 Gy of
IR, the number of positive γ-H2AX nuclear foci was
significantly reduced in all miR-BART transfected cells
(p < 0.01 in all cases, Figure 5A and supplementary
material, Figure S8A), suggesting that the ability of
the cells to recover from the IR-induced DNA damage
was impaired by the miR-BART activity. In accordance
with the γ-H2AX nuclear foci staining results, the DNA
repair capacity of the miR-BART transfected cells was
obviously repressed in the comet assay (p < 0.05). The
combined effect of these four miR-BARTs in enhancing
IR-induced DNA damage could also be demonstrated
(Figure 5B and supplementary material, Figure S8B).
More importantly, the long-term clonogenic survival
of the miR-BART transfected HeLa cells was signifi-
cantly reduced after IR treatment (Figure 5C). In our
experiments, approximately 50% of the untransfected
cells survived after exposure to 1 Gy of IR. In contrast,
the same dose of IR killed nearly 88% of the BART5-5p
(p = 0.008), 80% of the BART7-3p (p = 0.009), 75% of
the BART9-3p (p = 0.018), and 60% of the BART14-3p
(p = 0.048) transfected cells (Figure 5C). The effects
of miR-BART5-5p, miR-BART7-3p, and miR-BART9-3p
on augmenting the irradiation sensitivity of the trans-
fected cells were more obvious upon increasing the IR
dose to 2 Gy in the treatment (Figure 5D). Overall, these
results provide convincing evidence to support abundant
EBV-encoded miRNA expression as one of the underly-
ing mechanisms of the high radio-sensitivity of NPC.
EBV-miRNAs contribute to the maintenance of viral
latency by suppressing ATM activity
Consistent with our previous finding in EBV-infected
nasopharyngeal epithelial cells [24], the overexpression
of EBV immediate-early lytic protein, BZLF1 (Zta), in
C666-1 cells provoked the viral lytic cycle by dramati-
cally activating the expression of other viral early lytic
proteins, such as BRLF1 (Rta) and BMRF1 (EA-D). In
addition, BZLF1 expression in C666-1 cells could also
slightly elevate the activity of bothATMkinase (p-ATM)
and its downstream target (γ-H2AX) (Figure 6A).
ATM activity is known to promote EBV DNA
replication during lytic cycle reactivation [24,42].
Our new findings of the role of miR-BARTs in
ATM regulation prompted us to examine whether
miR-BARTs are involved in controlling viral replica-
tion. The results revealed that suppressing endogenous
BART7-3p, BART9-3p or BART14-3p activity in the
BZLF1-expressing C666-1 cells could activate the
ATM protein and its downstream effectors (p-ATM
and γ-H2AX), and these effects were accompanied by
increased expression of the BMRF1 protein (Figure 6A).
The expression levels of ATM and p-ATM were also
greatly increased in the cells transfected with inhibitors
of all four miR-BARTs (mean of ATM 1.98 and p-ATM
3.52) (supplementary material, Figure S5B) relative to
the individual inhibitor (mean of ATM 1.4–1.8 and
p-ATM 1.6–2.0) (Figure 6A). However, the combined
effects of all four miR-BARTs inhibitors did not lead
Figure 5. EBV-miRNAs suppress the DNA damage response to ionizing radiation. (A) Representative images of the H2AX nuclear foci
staining assay. Cells transfected with either miRNA mimics (miR-NEG) or a combination of four miR-BART mimics (All 4 miR-BARTs) were
treated with a single dose of 3 Gy irradiation, which was followed by immunostaining with the γ-H2AXser139 antibody 1 h post-irradiation.
Cells containing more than five γ-H2AX foci in the nucleus were considered positive and the percentage of γ-H2AX-positive cells was
calculated (n = 100). The mean ± SD for three independent experiments are shown. (B) Comet assays of the DNA repair capacity were
performed on NP69 and HeLa cells, which were treated with a single irradiation dose of 10 and 20 Gy, respectively. The tail moment of
the irradiated cells at 6 h is shown in the bar charts; mean ± SEM. Student’s t-test was conducted compared with the miR-NEG control.
*p < 0.05; **p < 0.01; ***p < 0.001. (C, D) Clonogenic survival assays. Approximately 200–1600 transfected HeLa cells were seeded into
a six-well plate and treated with a single dose of 0.5, 1 or 2 Gy irradiation. The cells were stained and colonies containing more than 30
cells were counted. The survival fraction was calculated by dividing the plating efficiency of the irradiated cells by the plating efficiency
of the untreated cultures. Statistical analyses using Student’s t-test were conducted and compared with the miR-NEG control. *p < 0.05;
**p < 0.01.
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Figure 6. BZLF1-induced virus reactivation is suppressed by miR-BARTs. (A) The BZLF1-expressing plasmid (1.25 μg) was co-transfected
with the indicated miR-BART inhibitors (10 μM) into C666-1 cells in a six-well plate. Cells were harvested for immunoblotting analysis
after 48 h. The expression of ATM, ATM downstream effectors (p-ATM and γ-H2AX), and the early viral lytic proteins (BRLF1 and BMRF1)
was analyzed. (B) The synergistic effects of BZLF1 and ATM on p-ATM, γ-H2AX, BRLF1, and BMRF1 expression in C666-1 cells. The cells
were co-transfected with ATM and BZLF1-expressing plasmids and protein expression was examined by immunoblotting. The two isoforms
of BMRF1 are indicated by arrows. The relative expression of the protein level was calculated for comparison.
to a further increase of the BMRF1 protein level (sup-
plementary material, Figure S5B), probably due to the
high level of BZLF1 which stimulates EBV reactivation
through the ATM signaling pathway (supplementary
material, Figure S9).
We further dissected the role of BZLF1 in the
ATM-induced viral lytic cycle by introducing ATM and
BZLF1 expression vectors, alone or in combination,
into C666-1 cells. In the absence of BZLF1 expression,
ATM alone had no effect on the expression of either
early viral lytic proteins or ATM downstream effec-
tors. Interestingly, BZLF1 and ATM synergistically
increased the expression of phospho-ATM, γ-H2AX,
and BMRF1 viral lytic protein (Figure 6B), indicating
that ATM might enhance BZLF1 activity. Therefore,
miR-BARTs may be responsible for maintaining viral
latency by suppressing ATM activity, which in turn
inhibits BZLF1 activity in viral lytic reactivation
(supplementary material, Figure S9).
Discussion
Here, we report that the miR-BART expression pat-
terns of six well-known EBV-positive NPC tumor
lines are significantly similar (supplementary material,
Figure S2). In addition, we unveil the novel suppres-
sive effect of BART5-5p, BART7-3p, BART9-3p, and
BART14-3p in modulating the ATM signaling pathway.
They occupied about 11% of the total EBV-encoded
miRNAs in NPCs (Figure 1B). The findings indicated
that these miR-BARTs contribute to ATM suppression in
this EBV-associated epithelial cancer. However, due to
the low miR-BART expression in EBV-associated lym-
phoid malignancies [43,44], previous highly sensitive
PAR-CLIP analysis only identified a number of cellular
miRNAs responsible for modulating ATM expression
[45,46]. Nevertheless, all of these reported cellular
miRNAs, except hsa-miR-26, are rarely expressed
in NPC samples, such as in C666-1 (supplementary
material, Table S10). The frequent downregulation of
miR-26 in NPC also suggests that the cellular miRNAs
are not involved in the downregulation of ATM in this
EBV-associated epithelial cancer [47].
More importantly, the expression of these four
miR-BARTs significantly inhibited both IR-induced
ATM kinase activity and BZLF1-induced viral lytic
reactivation (Figures 4–6). Intriguingly, a recent study
demonstrated that miRNAs in BART Cluster 1 can
also directly target BZLF1 expression in B-cells [48].
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Thus, the activity of BZLF1, a viral immediate-early
protein, is tightly controlled bymiR-BARTs via different
mechanisms. As various genotoxic stresses constantly
induce cellular DNA damage, the error-free homol-
ogous recombination (HR) pathway, which ensures
accurate DNA double-strand break (DSB) repair, is a
critical safeguard for maintaining genetic integrity for
cell survival [49,50]. ATM is an essential molecule in
the HR pathway, as it immediately responds to DNA
damage and activates several downstream effectors
to interrupt the cell cycle and stop DNA replication.
Downstream ATM effectors then facilitate DNA repair
or trigger a p53-dependent apoptotic pathway based
on the severity of the damage (supplementary mate-
rial, Figure S9) [51]. In the present study, we revealed
that EBV employs viral-encoded miRNAs to retard
the genotoxic stress-induced ATM kinase activity and
eventually promote cell death. Therefore, the frequent
downregulation of ATM in EBV-positive NPC may
partly explain the exceptionally high radio-sensitivity
of this deadly cancer.
Poly(ADP-ribose) polymerase (PARP) is an abun-
dant nuclear zinc-finger enzyme involved in the
base-excision repair of single-strand breaks (SSBs)
in the earliest DNA damage response. Inhibition of
PARP results in failure of the SSB repair machinery and
unrepaired lesions are converted into DSBs during DNA
replication [52]. HR-impaired cancer cells are therefore
sensitive to PARP inhibition. Based on this mecha-
nism, the PARP inhibitor olaparib has been evaluated
in clinical trials [53,54]. Currently, two independent
reports have shown that ATM-null cells exhibit selective
sensitivity to olaparib treatment [55,56]. Remarkably,
concurrent PARP inhibition also potentiates the cyto-
toxic effects of ionization radiation and platinum-based
DNA-damaging agents, thus maximizing the efficacy
of these treatments. This allows for the necessary treat-
ment doses to be reduced, thereby minimizing the side
effects of these therapies. Strikingly, a recent study
on EBV-negative NPC cell lines demonstrated that
olaparib could facilitate the tumor-inhibitory effects of
radiotherapy in in vivo models [33].
In conclusion, by uncovering the interaction between
miR-BARTs and the ATM signaling pathway, we report
for the first time the mechanisms responsible for low
ATM expression in EBV-positive NPC. It is likely that
miR-BARTs work co-operatively to modulate ATM in
controlling DNA damage repair and to maintain viral
latency. This finding may facilitate the development of
effective NPC therapies using DNA-damaging agents,
such as the PARP inhibitor.
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